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Abstract
Background: Human papilloma virus testing for oropharyngeal squamous-cell
carcinoma has been recommended by the National Comprehensive Cancer Network since 2012. We examine disparities, reported rates of human papillomavirus
(HPV) testing, and the impact on these findings of limitations with the variable in
database registries.
Methods: The HPV variable was queried for patients with oropharyngeal
squamous carcinoma (OPSCC) from 2013 to 2016 in National Cancer Data
Base (NCDB) and Surveillance, Epidemiology, and End Results (SEER).
Multivariable regression was used to identify disparities based on sociodemographic variables. Sensitivity analyses were used to investigate limitations of the
variable.
Results: Despite limitations in the HPV variable in the databases, there
was less than 100% adherence to recommended testing, and there were significant disparities in multiple sociodemographic variables. For example,
in NCDB 70% of white versus 60.4% of black patients were tested (odds
ratio [OR] 0.75, confidence interval [CI] 0.66–0.85, p ≤ 0.0001); in SEER
59.8% of white and 47.6% of black patients were tested (OR 0.73, CI
0.67–0.81; p ≤ 0.0001).
Conclusions: Disparities exist among patients undergoing testing for HPVassociated OPSCC and adherence to guideline recommended HPV testing has
been suboptimal. In addition, the HPV variable definition, especially as it
relates to p16 positivity, and use in these two registries should be improved.
KEYWORDS
disparities, head and neck cancer, HPV, oropharynx, testing
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1 | INTRODUCTION

2 | METHODS

The incidence of human papillomavirus (HPV)-related
oropharyngeal squamous carcinoma (OPSCC) is rapidly
increasing, and has surpassed cervical cancer as the leading HPV-related malignancy in the United States.1-3 HPV
tumor status has important prognostic and staging
implications,4-6
4-6
guides eligibility for current and future clinical trials, and may impact management algorithms for OPSCC.
Public health efforts at cancer prevention and control will
ideally use information about HPV status to target interventions aimed at specific sociodemographic groups at
risk for HPV-related OPSCC.7 In 2008, National Comprehensive Cancer Network (NCCN) guidelines were
updated to suggest HPV testing for patients with a
new diagnosis of OPSCC. Specifically, the guidelines
suggested testing for high risk HPV types either via
polymerase chain reaction or in situ hybridization.
The guidelines were further updated in 2012 and put
forth a strong recommendation to perform HPV testing
in newly diagnosed OPSCC.8
A recent investigation by Rotsides et al. utilizing the
National Cancer Data Base (NCDB) found significantly
higher rates of HPV negative cancer among patients who
were black and had lower socioeconomic status (SES).9
However, no data exist regarding potential sociodemographic
disparities in testing or on how well the guideline recommendation to test for HPV status is followed. Two large secondary cancer databases in the United States have included
a variable since 2010 describing both HPV testing and HPV
positivity for OPSCC. The variable has not been used to
examine trends or disparities in HPV testing, but has been
used for analyses of HPV positivity in the NCDB.10,11 The
other database, Surveillance, Epidemiology, and End Results
(SEER), has restricted access to the HPV variable due to the
potential of underreporting and incorrect coding of HPV testing and status. The reliability of the SEER and NCDB data
have not been assessed or compared in the literature. The
National Cancer Institute granted access to the SEER database for this analysis.
We queried the NCDB and SEER registry with the
primary goal of examining disparities among patients
undergoing HPV testing for OPSCC according to
sociodemographic, hospital, and clinical factors. Secondary and tertiary goals of this investigation included
assessing changes in HPV testing trends over time and
describing the HPV variable, including its components,
limitations related to our findings, and consistency
between the two databases. We queried both databases in
order to assess the validity of our findings and evaluate
SEER data that were heretofore not made available for
publication.

2.1 | Data sources and study population
We used the NCDB and SEER databases to study
patients diagnosed with OPSCC between 2013 and 2016
(International Classification of Disease for Oncology
ICD-O C019, C090, C091, C098-C104, C108, C109, C142;
histology codes 8073-8079 and 8083-8084). Registrars for
both databases were required to enter HPV status beginning in 2010; data were not available beyond 2016 from
either registry. The NCDB contains data from hospitalbased registries at Commission on Cancer accredited
hospitals, which collect data from over 70% of new cancer
cases in the United States each year, and over 80% of cases
from the oral cavity and pharynx.12 The SEER database
collects population-level data on approximately 28% of the
US population from 18 registries with appropriate minority representation, each case included is unique.13 SEER
registry data are publicly available for research purposes;
however, special access must be obtained for HPV-related
variables through the use of a data user agreement. The
NCDB and SEER databases are not mutually exclusive,
and some patients are included in both.
Figure 1 shows a flow diagram of inclusion and exclusion criteria for the cohort. Within NCDB, patients
18 years or older with histologically confirmed OPSCC
and documented stage were included. Within SEER,
patients 20 years or older, with the same histological confirmation were included. In order to avoid falsely
reporting that HPV testing was not performed when it
might have been, we excluded patients for whom HPV
status may have been checked, but may not have been
available to the registrar entering data. For NCDB, this
was defined as patients who were not diagnosed at the
reporting facility, but rather at a doctor's office or other
facility. We excluded patients for whom the HPV variable
was coded 988 (not applicable: information not collected
for this case). We excluded those coded 997 (test ordered,
results not in chart). For NCDB, we excluded patients
from hospitals that did not contribute cases for all 5 years
of this study population. SEER now only reports cases as
having been tested for HPV or not.

2.2 | Study variables
Patient demographics included age, sex, race, year of
diagnosis, tumor classification, and zip-code level information derived from 2012 American Community Survey
data about education (categorized as greater or less than
87% with high school diploma). Insurance status is coded
slightly differently between the two databases, with an
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FIGURE 1
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CONSORT diagram

additional category of “insured NOS” for SEER. Income
in the NCDB is based on 2012 American Community
Survey data and was categorized as greater or less than
$38 000. For SEER, the Yost socioeconomic index was used
as a proxy for income, with patients categorized into quintiles (low, 2, 3, 4, and high).14 The NCDB has additional
variables not available in SEER, including the patient's
Charlson-Deyo comorbidity index15 (0, 1, or ≥2), urban/
rural continuum, hospital characteristics including facility
type, and hospital volume (categorized in quartiles).
The HPV variable for head and neck cancers in both
databases is American Joint Committee on Cancer Collaborative Stage site-specific factor (SSF)-10. To calculate HPV
testing rates, we coded patients as “tested” if they were
documented HPV positive or negative, and not tested otherwise. For our primary analysis, the group apparently not
tested included two codes, “998; test not done” as well as
“999; unknown or no information.” SEER does not include
a “999; unknown or no information” code regarding the
HPV variable—patients are either tested or not.

2.3 | Sensitivity analyses
We performed two sensitivity analyses to deal with uncertainty regarding the data. The first uncertainty related to
the HPV variable: although we had already excluded
patients whose records were likely to be unavailable to the
registrar (at a physician's office, etc.), coding 999 still suggests a lower level of certainty than coding 998 that the
registrar found the pathology report and ascertained that
HPV status was not tested. Therefore, as a sensitivity analysis we excluded patients with a code of 999 (in which
HPV testing may have been completed and not reported
or not completed and not reported and therefore the status
of which was unknown at recording) and reanalyzed the
data to determine if the disparities in HPV testing rates
were still significant. This was only performed for the

NCDB data, as SEER does not include this code in relation
to the HPV testing variable.
The second uncertainty related to the year of HPV
testing, since HPV testing was only suggested by the
NCCN prior to 2012, and then more firmly recommended
starting in 2012. Furthermore, since the update, the literature has overwhelmingly demonstrated the importance
of HPV positivity in determining outcomes for oropharyngeal disease. Therefore, we performed a second sensitivity analysis, excluding data from years prior to 2015 to
assess for disparities in testing after the recommendation
was strengthened and because no arguments can be
made against HPV testing at this time point.

2.4 | Statistical analysis
We calculated the rates of HPV testing captured by the
cancer registries overall and by patient subgroups.
Bivariate logistic regression was performed to determine the
unadjusted odds ratios of being tested by patient subgroup.
Multivariable logistic regression was used to determine factors predictive of HPV testing. The two sensitivity analyses
with exclusion of code 999, and with exclusion of years
2013–2014 used the same regression model. All available
factors were used in these models. p-Values ≤0.05 were considered significant. Analyses were conducted using Stata
Statistical Software (Release 12.1; Stata Inc, College Station,
TX, USA).

3 | RESULTS
3.1 | Study population, overall testing
rates, and the HPV variable
In all, 33 622 patients in the NCDB and 23 621 patients
in SEER between 2013 and 2016 were diagnosed with
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histologically confirmed OPSCC. After applying exclusion
criteria, 14 636 patients in the NCDB and 22 088 in SEER
who should have received HPV testing according to
guideline recommendations were available for analysis
(Figure 1). Table 1 shows the frequency of SSF-10 codes
in the NCDB. Tables 2 and 3 describe the frequency of
testing overall and by patient subgroups as reported in
NCDB and SEER. The overall rate of testing was 68.9% in
NCDB and 57.4% in the SEER registry, assuming that
patients with a code of 999 (unknown or no information
in the NCDB only) were not tested. Testing rates
increased from 2013 to 2016; testing was as high as 74.4%
and 65% in later years in the NCBD and SEER,
respectively.

3.2 | Disparities in HPV testing by
patient subgroup
Tables 2 and 3 describe the rates of HPV testing in
patient subgroups for NCDB and SEER from 2013 to
2016, respectively, as well as the unadjusted odds that
belong to a subgroup influences testing rates. Figure 2
shows forest plots of the adjusted odds of multivariable
analysis of factors associated with HPV testing in the two
databases. Controlling for other variables, significant disparities in testing were observed in patient subgroups.
For example, in the NCDB 70% of white versus 60.4% of
black patients were tested; in SEER 59.8% of white and
47.6% of black patients were tested (NCDB OR 0.75, CI
0.66–0.85; SEER OR 0.73, CI 0.67–0.81, p ≤ 0.0001 for
both). Patients were less likely to be tested for HPV if
they were older compared to younger (e.g. <50 versus
older than 80: NCDB OR 0.49, CI 0.39–0.61; SEER OR
0.57, CI 0.49–0.66, p ≤ 0.0001 for both); if they had any
insurance other than private (e.g. private versus Medicare/Medicaid/Other Govt insurance NCDB OR 0.66, CI
0.60–0.72; SEER OR 0.72, CI 0.66–0.78, p ≤ 0.0001 for

TABLE 1

both); if they lived in zip-codes with lower educational
attainment compared to higher (NCDB OR 0.86, CI
0.78–0.94, p = 0.001); and if they lived in areas with
lower socioeconomic status (SEER SES-index high compared to low: OR 0.58, CI 0.52–0.63, p ≤ 0.0001). Patients
were less likely to receive HPV testing if they had a lower
stage of disease compared to higher (Stage IV versus I:
NCDB OR 1.49, CI 1.28–1.74, p ≤ 0.0001).

3.3 | Hospital-level differences in HPV
testing
Additional variables in the NCDB allowed comparison
of HPV testing rates based on hospital and geographic
characteristics. Patients were less likely to be tested for
HPV if they received care at a community hospital or
comprehensive community cancer center (NCDB only)
compared to academic hospitals and NCI-designated
comprehensive cancer centers. In addition, patients
were less likely to be tested if they received care at hospitals seeing a lower volume of OPSCC compared to
higher (NCDB only).

3.4 | Sensitivity analyses for HPV
variable and for year
In the NCDB sensitivity analysis relating to the HPV
variable, dropping patients with a code of 999 (unknown
or no information) changed the rate of testing to 88.1%
overall respectively, increasing to as high as 89.9% in
later years within NCDB (Figure 3). Looking at disparities in testing with code 999 dropped, the NCDB
(n = 11 442 compared to 14 636 available for analysis)
showed similar significant disparities in testing rates
after multivariable regression compared to the primary
analysis based on age, race, insurance status, income,

Total patients tested and results
NCDB
Number of patients (%)

SEER
Number of patients

Overall

14 636 (100.0)

22 088 (100.0)

Tested

10 081 (68.9)

12 685 (57.4)

HPV negative

3051 (20.8)

3925 (17.8)

HPV positive

7030 (48.0)

8760 (39.7)

4555 (31.1)

9403 (42.6)

Not apparently tested
998

Test not done

1361 (9.3)

N/A

999

Unknown or no information

3194 (21.8)

N/A

Abbreviations: HPV, human papillomavirus; NCDB, National Cancer Data Base; SEER, Surveillance, Epidemiology, and End Results.

8090 (55.3%)
4194 (28.7%)
632 (4.3%)

50–64 years

65–79 years

80 years or more

2789 (19.1%)

Female

1617 (11%)
423 (2.9%)

Black

Other

853 (5.8%)
7043 (48.1%)
282 (1.9%)

Uninsured

Medicaid, Medicare, Other Govt

Unknown

7051 (49.2%)

Less than 1 million

3644 (24.9%)
3642 (24.9%)

2014

2015

2507 (68.8%)

2474 (67.9%)

2283 (64.1%)

1908 (62.9%)

3031 (20.7%)

3563 (24.3%)

8153 (70.4%)

2013

Year diagnosed

<$38 000

$38 000 or greater

4315 (64.8%)

5758 (72.3%)

4775 (67.7%)

5078 (69.8%)

165 (58.5%)

4503 (63.9%)

545 (63.9%)

4868 (75.4%)

283 (66.9%)

977 (60.4%)

8821 (70%)

1807 (64.8%)

8274 (69.8%)

339 (53.6%)

2772 (66.1%)

5664 (70%)

1306 (75.9%)

Tested for HPV
10 081 (68.9%)
Tested for HPV

11 577 (79.3%)

6664 (45.6%)

≤87% w/ HS degree

Income

7959 (54.4%)

>87% w/ HS degree

Education

7271 (50.8%)

1 million or more

Urban/rural continuum

6458 (44.1%)

Private

Insurance status

12 596 (86.1%)

White

Race

11 847 (80.9%)

Male

Sex

1720 (11.8%)

<50 years

Age at diagnosis

Overall
14 636 (100%)
Overall

1.55 (1.31–1.83)

1.35 (1.11–1.62)

1 [Reference]

0.71 (0.66–0.78)

1 [Reference]

0.70 (0.66–0.75)

1 [Reference]

0.91 (0.84–0.97)

1 [Reference]

0.46 (0.36–0.59)

0.58 (0.54–0.62)

0.58 (0.50–0.67)

1 [Reference]

0.87 (0.70–1.06)

0.65 (0.59–0.73)

1 [Reference]

0.80 (0.73–0.87)

1 [Reference]

0.37 (0.30–0.44)

0.62 (0.54–0.70)

0.74 (0.66–0.84)

1 [Reference]

Unadjusted OR (95% CI)

National Cancer Data Base (NCDB) unadjusted and adjusted odds ratios of human papillomavirus (HPV) testing

Patients with OPSCC
Characteristic

TABLE 2

0.49 (0.39–0.61)

≤0.0001

0.58 (0.44–0.76)

≤0.0001

1.21 (1.08–1.34)
1.25 (1.12–1.39)

≤0.0001

1 [Reference]

0.93 (0.83–1.04)

1 [Reference]

0.86 (0.78–0.94)

1 [Reference]

0.97 (0.89–1.06)

0.002

≤0.0001

≤0.0001

≤0.0001

0.006

0.66 (0.60–0.72)

≤0.0001

1 [Reference]

0.69 (0.59–0.82)

1 [Reference]

0.77 (0.61–0.97)

0.75 (0.66–0.85)

1 [Reference]

0.91 (0.82–1.01)

≤0.0001

0.168

≤0.0001

≤0.0001

0.75 (0.64–0.87)

≤0.0001

1 [Reference]

0.74 (0.64–0.84)

1 [Reference]

Adjusted OR (95% CI)

≤0.0001

p-value

(Continues)

≤0.0001

0.001

0.189

0.001

0.512

≤0.0001

≤0.0001

≤0.0001

0.029

≤0.0001

0.062

≤0.0001

≤0.0001

≤0.0001

p-value
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(Continued)

6443 (71.9%)

8957 (67.2%)

5486 (37.9%)
1810 (12.5%)

Community

Comprehensive community

INCP

2625 (73.6%)

3754 (25.6%)
3567 (24.4%)

44–76 pts

1153 (8%)
1216 (8.4%)

East South Central

West North Central

894 (73.5%)

715 (62%)

1833 (67.3%)

2418 (69.4%)

3485 (24.1%)
2722 (18.8%)

South Atlantic

East North Central

1368 (72.7%)

1881 (13%)

Middle Atlantic

697 (78.5%)

888 (6.1%)

New England

Geographic region

77–245 pts

2604 (69.4%)

3518 (24%)

25–43 pts

2400 (68.2%)

3797 (25.9%)

2452 (64.6%)

1265 (69.9%)

3768 (68.7%)

900 (63.9%)

4018 (69.8%)

1–24 pts

Hospital volume

5755 (39.8%)
1408 (9.7%)

Academic/NCI CCC

Facility type

Hospital characteristics

406 (67.4%)
233 (70.8%)

602 (4.1%)
329 (2.2%)

2

>3

7913 (69.3%)
1529 (66.8%)

11 416 (78%)
2289 (15.6%)

1

0

Charlson-Deyo Comorbidity Count (CCI)

IV

1728 (71.8%)

2406 (18%)

III

775 (68.9%)

1125 (8.4%)

II

527 (62.2%)

2817 (74.4%)

Tested for HPV
10 081 (68.9%)
Tested for HPV

847 (6.4%)

3787 (25.9%)

Overall
14 636 (100%)
Overall

I

AJCC stage

Clinical characteristics

2016

Patients with OPSCC
Characteristic

TABLE 2

0.76 (0.62–0.93)

0.45 (0.37–0.55)

0.57 (0.47–0.68)

0.62 (0.52–0.74)

0.73 (0.61–0.88)

1 [Reference]

1.53 (1.38–1.69)

1.24 (1.13–1.37)

1.18 (1.07–1.30)

1 [Reference]

1.00 (0.89–1.13)

0.95 (0.88–1.03)

0.77 (0.68–0.87)

1 [Reference]

1.07 (0.84–1.37)

0.92 (0.77–1.09)

0.89 (0.81–0.98)

1 [Reference]

1.76 (1.51–2.04)

1.69 (1.43–2.00)

1.27 (1.05–1.54)

1 [Reference]

1.56 (1.34–1.80)

Unadjusted OR (95% CI)
1.74 (1.55–1.95)

≤0.0001

1.49 (1.28–1.74)

≤0.0001

1.40 (1.24–1.59)
1.99 (1.72–2.29)

≤0.0001
≤0.0001

0.66 (0.52–0.83)

0.43 (0.34–0.54)

≤0.0001
0.009

0.57 (0.47–0.70)
0.50 (0.41–0.61)

≤0.0001
≤0.0001

0.66 (0.53–0.81)

0.0012

1 [Reference]

1.22 (1.08–1.36)

1 [Reference]

1.13 (0.98–1.30)

1.19 (1.07–1.33)

1.19 (1.00–1.41)

1 [Reference]

1.24 (0.95–1.62)

1.10 (0.90–1.33)

1.03 (0.92–1.15)

0.001

0.954

0.193

≤0.0001

0.559

0.332

0.018

1.51 (1.27–1.80)

≤0.0001

1 [Reference]

1.37 (1.12–1.66)

0.013

1 [Reference]

Adjusted OR (95% CI)

p-value

≤0.0001

≤0.0001

≤0.0001

≤0.0001

≤0.0001

≤0.0001

≤0.0001

0.001

0.093

0.002

0.048

0.121

0.365

0.618

≤0.0001

≤0.0001

0.002

≤0.0001

p-value
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Note: New England (CT, MA, ME, NH, RI, VT); Middle Atlantic (NJ, NY, PA); South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV); East North Central (IL, IN, MI, OH, WI); East South Central (AL, KY, MS, TN);
West North Central (IA, KS, MN, MO, ND, NE, SD); West South Central (AR, LA, OK, TX); Mountain (AZ, CO, ID, MT, NM, NV, UT, WY); Pacific (AK, CA, HI, OR, WA).

0.001

0.004

0.62 (0.47–0.82)

0.010

0.72 (0.57–0.90)

≤0.0001
0.61 (0.48–0.78)

1039 (73.7%)

521 (3.6%)

1409 (9.7%)

Mountain

Pacific

360 (69.1%)

0.77 (0.63–0.94)

≤0.0001
0.30 (0.24–0.38)
≤0.0001
0.31 (0.25–0.38)
1184 (8.2%)
West South Central

627 (53%)

Adjusted OR (95% CI)
Unadjusted OR (95% CI)
Tested for HPV
10 081 (68.9%)
Tested for HPV
Overall
14 636 (100%)
Overall
Patients with OPSCC
Characteristic

(Continued)
TABLE 2

7

p-value

p-value
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clinical stage, hospital volume, and geographic region
(see Appendix Table A1).
The second sensitivity analysis was performed to evaluate if disparities in testing existed and/or improved following changes in the strength of testing recommendations.
Starting in 2008, the NCCN guidelines “suggested” HPV
testing in new diagnoses of oropharyngeal OPSCC; this
was later changed to “recommended” in 2012. In performing the sensitivity analysis, we hoped to assess the
impact of the guideline strength on rates of HPV testing.
From 2015 to 2016 (the most recent available data with
the greatest strength of recommendation), there were still
significant disparities in testing between the two databases.
In the NCDB, patients were less likely to have undergone
HPV testing if they were older (>80 years old), had government insurance, presented at higher clinical stage, or
were treated in certain geographic regions (data not
shown). Within the SEER database, there were disparities
based on age, sex, race, type of insurance, and income
(data not shown).

4 | DISCUSSION
Testing the tumors of newly diagnosed patients with
OPSCC for HPV positivity was first suggested in the
2008 NCCN guidelines and recommended in 2012.
While the HPV variable has been recorded in NCDB
and SEER registries since 2010, it has not previously
been used to assess disparities in HPV testing among
different sociodemographic groups or to evaluate rates
of testing among patients with newly diagnosed
OPSCC. The HPV variable in the NCDB has been used
for analysis according to HPV positivity.10,11 SEER has
not made the variable available in publicly released
data because of possible reliability issues with variable
coding. The issues of quality of the variable occur in
both NCDB and SEER as the coding instructions and
data collection practices are the same. The variable
itself, including its limitations related to findings of
testing rates and positivity, and consistency between
the two databases, has not been evaluated. We sought
to identify disparities in testing, evaluate trends in
HPV testing from 2013 to 2016, and assess the limitations of the variable used to indicate the status of HPV
testing and positivity within the two databases. Our
purpose in including both databases in our analysis
was to confirm the validity of our findings and to
examine SEER data that were not made available for
public use.
Despite limitations in the HPV variable, we found
that HPV testing rates increased from 2013 to 2016 as
reported in both NCDB and SEER, but remained below
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TABLE 3
testing

Surveillance, Epidemiology, and End Results (SEER) unadjusted and adjusted odds ratios of human papillomavirus (HPV)

Patients with OPSCC

Overall
22 088 (100%)

Tested for HPV
12 685 (57.4%)

Characteristic

Overall

Tested for HPV

Unadjusted OR (95% CI)

p-value

Adjusted OR (95% CI)

p-value

Age at diagnosis
<50
50–64

2445 (11.1%)
11 097 (50.3%)

1338 (54.7%)

1 [Reference]

6663 (60%)

1.24 (1.14–1.36)

1 [Reference]
≤0.0001

1.11 (1.01–1.22)

0.026

65–79

7201 (32.6%)

4080 (56.7%)

1.08 (0.99–1.19)

0.096

0.90 (0.81–0.99)

0.036

≥80

1336 (6.1%)

604 (45.2%)

0.68 (0.60–0.78)

≤0.0001

0.57 (0.49–0.66)

≤0.0001

Sex
Male

17 961 (81.3%)

10 535 (58.7%)

4127 (18.7%)

2150 (52.1%)

White

18 218 (82.5%)

10 895 (59.8%)

Black

2137 (9.7%)

1017 (47.6%)

0.61 (0.56–0.67)

≤0.0001

0.73 (0.67–0.81)

≤0.0001

Other

1733 (7.8%)

773 (44.6%)

0.54 (0.49–0.60)

≤0.0001

0.52 (0.47–0.58)

≤0.0001

Female

1 [Reference]
0.77 (0.72–0.82)

1 [Reference]
≤0.0001

0.85 (0.79–0.91)

≤0.0001

Race
1 [Reference]

1 [Reference]

Insurance status
Insured
Uninsured

17 692 (80.1%)
660 (3%)

10 555 (59.7%)

1 [Reference]

320 (48.5%)

0.64 (0.55–0.74)

1 [Reference]
≤0.0001

0.68 (0.57–0.80)

≤0.0001

Medicaid

3330 (15.1%)

1645 (49.4%)

0.66 (0.61–0.71)

≤0.0001

0.72 (0.66–0.78)

≤0.0001

Unknown

406 (1.8%)

165 (40.6%)

0.46 (0.38–0.57)

≤0.0001

0.43 (0.34–0.53)

≤0.0001

High

4382 (21.1%)

2884 (65.8%)

4

4304 (20.8%)

2569 (59.7%)

0.77 (0.71–0.84)

≤0.0001

0.78 (0.71–0.85)

≤0.0001

3

4199 (20.2%)

2398 (57.1%)

0.69 (0.63–0.76)

≤0.0001

0.70 (0.64–0.77)

≤0.0001

2

4023 (19.4%)

2161 (53.7%)

0.60 (0.55–0.66)

≤0.0001

0.61 (0.56–0.67)

≤0.0001

Low

3833 (18.5%)

1920 (50.1%)

0.52 (0.48–0.57)

≤0.0001

0.58 (0.52–0.63)

≤0.0001

2013

5293 (24%)

2625 (49.6%)

2014

5449 (24.7%)

3001 (55.1%)

1.25 (1.16–1.34)

≤0.0001

1.27 (1.17–1.38)

≤0.0001

2015

5481 (24.8%)

3243 (59.2%)

1.47 (1.37–1.59)

≤0.0001

1.50 (1.38–1.62)

≤0.0001

2016

5865 (26.6%)

3816 (65.1%)

1.89 (1.75–2.04)

≤0.0001

1.97 (1.82–2.14)

≤0.0001

SES quintile
1 [Reference]

1 [Reference]

Year diagnosed
1 [Reference]

100% adherence. Although the numbers cannot be
known exactly due to the limitations with the variable,
testing rates remained as low as 65%–74% in 2016, the
last year of available data. With the most stringent exclusion criteria, maximal testing rates captured by the
NCDB may have been as high as 90% in 2016; however,
testing rates were unlikely to have been this high, given
that this required exclusion of cases where the registrar
marked “999: unknown or no information.” Ultimately,
regardless of what the true absolute numbers tested are,
we found that improvements in testing rates across the
United States over time have been modest at best. Additionally, significant disparities in testing were present in

1 [Reference]

both databases. Specifically, we found that patients who
were older, black, and without private insurance were significantly less likely to undergo HPV testing. The NCDB
demonstrated differences in testing rates according to hospital characteristics, notably with less testing performed in
hospitals with lower volumes of head and neck cancer.
Regarding the variable itself, we found that registrars were
consistent in their coding between the two databases, and
that sensitivity analysis did not change the overall results.
We are not aware of any studies that have examined HPV testing rates and disparities in testing among
patients with OPSCC. There is literature on disparities
in HPV positivity, including a recent publication that
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FIGURE 2

9

Odds of undergoing human papillomavirus (HPV) testing

describes significantly higher rates of HPV negative disease among black patients compared to white and the
association of race and SES with poorer survival outcomes.9 Regarding testing, one Canadian study described
self-reported use of HPV testing in 2012 among primarily

Canadian physicians to be 67%, with higher use among
academic and higher oncologic-volume practices.16 Those
findings fit with our data of suboptimal adherence to the
guideline recommendations, and lower rates of testing
according to hospital characteristics.
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F I G U R E 3 Human papillomavirus (HPV) testing rates
over time [Color figure can be viewed at wileyonlinelibrary.com]

In our data set, disparities related to sociodemographic
factors remained even after guidelines strongly recommending testing for OPSCC were published in 2012.
Disparities in HPV testing may reflect differences in access
to pathologists and pathology departments that perform
the test. It has been shown that guideline changes are
slowly adopted in the field of head and neck and thyroid
cancer.17,18 In addition, HPV testing can be expensive and
the various methodologies are not yet standardized.17,19 In
the Canadian study, the most common reason given for
not testing was the cost of the tests.16 In addition, the finding of disparities in testing as relating to the type of insurance and patient income highlights the potential impact of
heath care reimbursement and economics of HPV testing
on cancer care. It may be that patients with lower income
and nonprivate insurance type are unable to obtain care at
higher volume or more experienced cancer centers with
greater resources and access to HPV testing.
Yet access to a facility that performs the test, the year of
diagnosis, implementation of guideline suggestions and recommendations, and strength of recommendations cannot
entirely explain disparities based on age, sex, and race, since
differences in testing still existed when all sociodemographic
factors and years were controlled for. Instead, some of the
disparities in HPV testing may reflect biases in presumed
risk-related behaviors regarding the use of tobacco, alcohol,
sexual habits, and presumed differences in HPV positivity,
leading clinicians or pathologists to perform the test only in
certain cases.
Prior to our current understanding of the differences
in HPV positive versus HPV negative disease, it may be
argued that HPV testing did not significantly alter treatment and, therefore, HPV testing did not offer additional
value in disease management. This may also explain why
the rate of testing continued to be low despite changes
in guidelines, particularly in nonacademic centers. Of
course, the difference in prognosis that HPV status infers
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on patients with OPSCC is now well described and this
understanding has started to impact the treatment of
HPV-related OPSCC. Updates in OPSCC staging systems
reflect the differences in prognosis and survival between
HPV-positive and HPV-negative diseases. Beyond adding
important prognostic information, HPV status has now
prompted efforts to assess oncologic outcomes following
de-escalation therapy for HPV OPSCC. The results of
these trials may significantly alter future therapies and
management algorithms for HPV-positive OPSCC, which,
in turn, may significantly impact both disease-specific
and treatment-related outcomes. Given the potentially
long-lasting impact of HPV status on treatments and outcomes, adequate testing for this factor becomes even
more critical.
More widespread adoption of HPV testing will likely
require a change in both access and standardization of
testing as well as a mediation of whatever biases might
prevent some patients from receiving testing, particularly
in light of increasing incidence of HPV-associated OPSCC
and its impact on treatment and outcomes.
Another important finding of this paper is that the
HPV variable itself, including how it is defined in the
coding dictionary, and how registrars are instructed to
use it, could be improved. One limitation of the variable
that impacts the analyses of testing rates and disparities
is that a significant number of patients (22% in NCDB)
are coded as 999 “unknown or no information.” Even
when excluding this group, a significant number of
patients still apparently did not receive testing. Furthermore, sensitivity analyses excluding these patients from
the group apparently not tested confirms that disparities
in testing still exist.
Another important limitation of the variable, as currently defined, is that it does not distinguish between
methods of testing. Diagnosis of the viral infection of the
tumor tissue is performed with DNA in situ hybridization
(ISH) or PCR HPV DNA detection, a method that also can
provide the subtype of HPV.20 An alternative and less
expensive method is immunohistochemical (IHC) analysis
for the presence of p16, a tumor suppressor protein
shown to be present in most HPV-positive tumors and
absent in HPV-negative tumors.21 p16 status by IHC is
similarly prognostic and p16 positivity is therefore
often used interchangeably with HPV positivity. For
instance, the summary of a pathology reports may state
something to the effect of “p16 testing indicates that
the tumor is HPV-related.”
For registrars, there is no separate code for p16 IHC
positivity. Faced with a p16 test alone, a registrar therefore is forced to make one of the following errors: The
most common HPV subtypes using ISH or PCR are subtypes 16 and 18, and the registrars may incorrectly code

HUSAIN ET AL.

p16 positivity as HPV positive, type 16. By anecdotal
report from officials of the SEER database, this is the
most common error, and is reflected in the high number
of HPV-positive patients coded as type 16 as seen in
Appendix Table A2. Alternatively, as this test was not
mentioned in the coding instructions as a valid test for
ascertaining HPV status, someone may inappropriately
mark as “test not done” for a patient who may in fact
have undergone testing. Similarly, a tumor may be marked p16 positive without specifically articulating or
referencing HPV status, which may be interpreted by an
uneducated coder who is not aware of p16 status as a surrogate for HPV status as “test not done.” Finally, they
may mark “test performed but results not in the chart”
(code 997, excluded in Figure 1) if there is ambiguous terminology according to registry definitions. For example,
if the pathologist stated “p16 positive suggestive for HPV
infection,” this could have been coded as unknown HPV
status because “suggestive” is considered an ambiguous
term in cancer surveillance.
Two of the SEER registries performed evaluation of
the quality of the HPV variable. The major findings revealed underreporting of HPV status (9% and 16%, respectively) mainly due to not coding HPV status if it was
determined by p16 IHC. A second cause of underreporting
resulted from not coding or miscoding of p16 overexpression as HPV type 16 in a very large number of cases.
However, overall HPV status (positive or negative) had
high degrees of accuracy in both quality studies. Unfortunately, there remain many pitfalls for coding of the HPV
variable in both databases that may significantly impact
the evaluation of HPV positivity differences among different demographic groups within the population.
This issue with the HPV variable should be addressed.
As of this writing, SEER has begun to examine the
quality of this data and is investigating correction of the
variable. Until the variable is improved, it will be difficult
to be confident about true HPV testing rates in the population, to distinguish between the methods of testing, or
to draw any conclusions about HPV subtypes. These
issues do not, however, affect the overall message of the
results of this analysis, because patients are in fact mostly
appropriately marked as tested for HPV even if marked in
the wrong box because the test was done with p16 IHC,
and because observed disparities were robust between
databases and sensitivity analyses.
Some considerations in improving the HPV variable
in both databases should be given to adding fields to help
differentiate between p16 IHC, HPV ISH, and HPV PCR.
Not only would these fields identify method of testing but
may negate some of the mistakes associated with interpreting test results (such as coding p16 positivity as
HPV type 16 positivity). These changes may also inform
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inexperienced coders of the validity and availability of
multiple different testing methodologies and prevent
inappropriate coding as “not tested” when faced with
ambiguous results.
HPV positivity, rather than HPV testing, is another
issue raised by this data. It would be valuable for
researchers to be able to use national databases to
examine sociodemographic differences in HPV positivity, survival, and treatment differences. Many cohort
studies have examined sociodemographic differences
in HPV positivity according to race, but they have used
small and/or local samples and have come to different
conclusions.22-25 The current study raises questions
about these types of analyses using national databases,
because of the potential impact of variable limitations
and testing disparities. These questions deserve further
analysis examining HPV positivity rates in these
databases.
In summary, our findings suggest that although
the use of HPV testing has increased over time for
patients with OPSCC, there was still significant
underuse of testing up to 2016 despite changes in the
strength of recommendations for HPV testing in
national cancer guidelines. More important, however,
is the finding of the existence of significant disparities
in testing among patients within different demographic groups with potentially significant impacts on
treatment and disease outcomes. Additional questions
raised by these analyses, which are beyond the scope
of this paper, include whether limitations with the
variable or disparities in testing have implications for
analyses of sociodemographic differences in HPVpositivity and HPV-associated OPSCC survival. Even
with the limitations of the variable and changes in
guideline adherence over time, these findings are
robust and have important implications. HPV positivity offers important prognostic information and guides
enrollment in current and future clinical trials for
patients with OPSCC. Efforts to improve rates of testing in the population, decrease disparities among
groups tested, and improve the coding of the HPV
variable in national databases are important for the
coming decades when HPV-associated OPSCC will be
increasingly prevalent.
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TABLE A1
SSF-10 “999”

National Cancer Data Base (NCDB) unadjusted and adjusted odds ratios of human papillomavirus (HPV) testing, excluding

Patients with OPSCC

Overall
11 442
Overall

Tested for HPV
10 081 (88.1%)
Tested
for HPV

Characteristic

Unadjusted
OR (95% CI)

<50 years

1431 (12.5%)

1306 (91.3%)

1 [Reference]

50–64 years

6396 (55.9%)

5664 (88.6%)

0.74 (0.61–0.90)

0.003

0.69 (0.55–0.87)

0.002

p-value

Adjusted OR
(95% CI)

p-value

Age at diagnosis
1 [Reference]

65–79 years

3178 (27.8%)

2772 (87.2%)

0.65 (0.53–0.81)

≤0.0001

0.77 (0.60–1.00)

0.048

80 years or more

437 (3.8%)

339 (77.6%)

0.33 (0.25–0.44)

≤0.0001

0.36 (0.25–0.51)

≤0.0001

Male

9355 (81.8%)

8274 (88.4%)

1 [Reference]

Female

2087 (18.2%)

1807 (86.6%)

0.84 (0.73–0.97)

White

9942 (86.9%)

8821 (88.7%)

1 [Reference]

Black

1173 (10.3%)

977 (83.3%)

0.63 (0.54–0.75)

≤0.0001

0.75 (0.62–0.92)

0.005

Other

327 (2.9%)

283 (86.5%)

0.82 (0.59–1.13)

0.222

0.73 (0.51–1.05)

0.089

Private

5345 (46.7%)

4868 (91.1%)

1 [Reference]

Uninsured

638 (5.6%)

545 (85.4%)

0.57 (0.45–0.73)

Medicaid, Medicare, Other Govt

5268 (46%)

4503 (85.5%)

0.58 (0.51–0.65)

≤0.0001

0.62 (0.53–0.73)

≤0.0001

Unknown

191 (1.7%)

165 (86.4%)

0.62 (0.41–0.95)

0.028

0.73 (0.46–1.16)

0.180

1 million or more

5712 (51%)

5078 (88.9%)

1 [Reference]

Less than 1 million

5479 (49%)

4775 (87.2%)

0.85 (0.76–0.95)

>87% w/ HS degree

6446 (56.4%)

5758 (89.3%)

1 [Reference]

≤87% w/ HS degree

4987 (43.6%)

4315 (86.5%)

0.77 (0.69–0.86)

$38 000 or greater

9148 (80.1%)

8153 (89.1%)

1 [Reference]

<$38 000

2271 (19.9%)

1908 (84%)

0.64 (0.56–0.73)

Sex
1 [Reference]
0.018

1.05 (0.89–1.23)

0.590

Race
1 [Reference]

Insurance status
1 [Reference]
≤0.0001

0.60 (0.46–0.78)

≤0.0001

Urban/rural continuum
1 [Reference]
0.004

0.87 (0.76–1.00)

0.047

Education
1 [Reference]
≤0.0001

0.98 (0.84–1.14)

0.760

Income
1 [Reference]
≤0.0001

0.77 (0.64–0.91)

0.002

Year diagnosed
2013

2629 (23%)

2283 (86.8%)

1 [Reference]

≤0.0001

1 [Reference]

2014

2834 (24.8%)

2474 (87.3%)

1.04 (0.89–1.22)

0.614

1.02 (0.86–1.22)

0.809

2015

2845 (24.9%)

2507 (88.1%)

1.12 (0.96–1.32)

0.152

1.10 (0.93–1.32)

0.272

2016

3134 (27.4%)

2817 (89.9%)

1.35 (1.15–1.58)

0.000

1.46 (1.22–1.74)

≤0.0001

Clinical characteristics
AJCC stage
I

637 (6%)

527 (82.7%)

1 [Reference]

II

897 (8.4%)

775 (86.4%)

1.33 (1.00–1.76)

0.049

1 [Reference]
1.46 (1.09–1.96)

0.011

III

1915 (18%)

1728 (90.2%)

1.93 (1.50–2.49)

≤0.0001

1.98 (1.53–2.58)

≤0.0001

IV

7200 (67.6%)

6443 (89.5%)

1.78 (1.43–2.21)

≤0.0001

1.82 (1.45–2.28)

≤0.0001

Charlson-Deyo Comorbidity Count (CCI)
0

8952 (78.2%)

7913 (88.4%)

1 [Reference]

1 [Reference]

1

1755 (15.3%)

1529 (87.1%)

0.89 (0.76–1.04)

0.132

1.08 (0.91–1.28)

0.399

2

470 (4.1%)

406 (86.4%)

0.83 (0.64–1.09)

0.187

1.01 (0.75–1.36)

0.964

>3

265 (2.3%)

233 (87.9%)

0.96 (0.66–1.39)

0.814

1.15 (0.76–1.73)

0.508

(Continues)
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TABLE A1

(Continued)

Patients with OPSCC

Overall
11 442
Overall

Tested for HPV
10 081 (88.1%)
Tested
for HPV

Characteristic

Unadjusted
OR (95% CI)

4561 (40.4%)

4018 (88.1%)

1 [Reference]

p-value

Adjusted OR
(95% CI)

p-value

Hospital characteristics
Facility type
Academic/ NCI CCC

1 [Reference]

Community

1039 (9.2%)

900 (86.6%)

0.88 (0.72–1.07)

0.190

1.12 (0.85–1.47)

0.431

Comprehensive community

4243 (37.6%)

3768 (88.8%)

1.07 (0.94–1.22)

0.298

1.18 (0.98–1.41)

0.075

INCP

1451 (12.8%)

1265 (87.2%)

0.92 (0.77–1.10)

0.353

0.91 (0.74–1.13)

0.401

1–24 pts

2833 (24.8%)

2452 (86.6%)

1 [Reference]

25–43 pts

2696 (23.6%)

2400 (89%)

1.26 (1.07–1.48)

0.005

1.27 (1.05–1.54)

0.013

44–76 pts

2956 (25.8%)

2604 (88.1%)

1.15 (0.98–1.34)

0.078

1.26 (1.03–1.54)

0.025

77–245 pts

2957 (25.8%)

2625 (88.8%)

1.23 (1.05–1.44)

0.010

1.55 (1.24–1.94)

≤0.0001

Hospital volume
1 [Reference]

Geographic region
New England

754 (6.7%)

697 (92.4%)

1 [Reference]

Middle Atlantic

1557 (13.8%)

1368 (87.9%)

0.59 (0.43–0.81)

0.0009

1 [Reference]
0.55 (0.39–0.77)

0.001

South Atlantic

2713 (24%)

2418 (89.1%)

0.67 (0.50–0.90)

0.008

0.68 (0.49–0.94)

0.020

East North Central

2095 (18.5%)

1833 (87.5%)

0.57 (0.42–0.77)

≤0.0001

0.56 (0.40–0.78)

0.001

East South Central

839 (7.4%)

715 (85.2%)

0.47 (0.34–0.66)

≤0.0001

0.50 (0.34–0.73)

≤0.0001

West North Central

1011 (9%)

894 (88.4%)

0.63 (0.45–0.87)

0.005

0.62 (0.43–0.89)

0.010

West South Central

756 (6.7%)

627 (82.9%)

0.40 (0.29–0.55)

≤0.0001

0.41 (0.29–0.59)

≤0.0001

Mountain

445 (3.9%)

360 (80.9%)

0.35 (0.24–0.50)

≤0.0001

0.38 (0.26–0.58)

≤0.0001

Pacific

1124 (10%)

1039 (92.4%)

1.00 (0.71–1.42)

0.998

1.00 (0.68–1.48)

0.988

Note: New England (CT, MA, ME, NH, RI, VT); Middle Atlantic (NJ, NY, PA); South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV); East North Central (IL,
IN, MI, OH, WI); East South Central (AL, KY, MS, TN); West North Central (IA, KS, MN, MO, ND, NE, SD); West South Central (AR, LA, OK, TX); Mountain
(AZ, CO, ID, MT, NM, NV, UT, WY); Pacific (AK, CA, HI, OR, WA).

TABLE A2

SSF-10 frequencies, National Cancer Data Base (NCDB) and Surveillance, Epidemiology, and End Results (SEER)
NCDB
Number of patients (%)

SEER
Number of patients (%)

Overall

14 636 (100.0)

22 088 (100.0)

Tested

10 081 (68.9)

12 685 (57.4)

Code

Code

Meaning

0

HPV negative

3051

N/A

10

HPV positive, low-risk types only

285

N/A

20

HPV positive, specified high risk types other than 16 and
18

444

N/A

30

HPV positive, type 16

4630

N/A

40

HPV positive, type 18

19

N/A

50

HPV positive, types 16 and 18

468

N/A

60

HPV positive, high risk NOS

344

N/A

70

HPV positive, NOS

Not tested

840

N/A

4555 (31.1)

9403 (42.6)

998

Test not done

1361

N/A

999

Unknown or no information

3194

N/A

